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Cutaneous Anaplastic Large Cell Lymphoma and
Peripheral T-Cell Lymphoma NOS Show Distinct
Chromosomal Alterations and Differential Expression
of Chemokine Receptors and Apoptosis Regulators
Marloes S. van Kester1, Cornelis P. Tensen1, Maarten H. Vermeer1, Remco Dijkman1, Aat A. Mulder1,
Karoly Szuhai2, Rein Willemze1 and Remco van Doorn1
Primary cutaneous anaplastic large cell lymphoma (C-ALCL) has an indolent clinical course and favorable
prognosis. On the contrary, primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTL-NOS)
shows aggressive clinical behavior. To identify genomic events relevant in the pathogenesis of these cutaneous
T-cell lymphomas (CTCLs), we carried out array-based comparative genomic hybridization (CGH) analysis.
Simultaneously, gene expression profiling was conducted to gain insight into gene expression programs
associated with the different clinical behavior of these CTCLs. C-ALCL was characterized by gains on
chromosome 7q and 17q and losses on 6q and 13q. PTL-NOS similarly showed gains on 7q and 17q, but was
distinguished by gains on chromosome 8 and loss of a focal overlapping region on 9p21. We identified minimal
common regions harboring candidate oncogenes and tumor suppressor genes in C-ALCL and PTL-NOS. Genes
with a role in lymphocyte chemotaxis, apoptosis, and proliferation were overrepresented among genes
differentially expressed between these lymphomas. C-ALCL showed higher expression of the skin-homing
chemokine receptor genes CCR10 and CCR8, which may explain the lower tendency to disseminate to
extracutaneous sites. Furthermore, C-ALCL and PTL-NOS showed aberrant expression of distinct genes
implicated in apoptosis and proliferation, such as IRF4/MUM1 and PRKCQ, which may account for differences in
clinical aggressiveness.
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INTRODUCTION
Primary cutaneous anaplastic large cell lymphoma (C-ALCL),
formerly designated as primary cutaneous CD30-positive
large T-cell lymphoma, is a T-cell lymphoma composed
of large cells with an anaplastic, pleomorphic, or immuno-
blastic cytomorphology, which show expression of the CD30
receptor (Willemze et al., 2005). Most patients present with
solitary or localized skin tumors that have a tendency to
regress spontaneously. C-ALCL has an indolent clinical
behavior and rarely shows extracutaneous dissemination.
This cutaneous T-cell lymphoma (CTCL) is commonly treated
with radiotherapy and has an excellent prognosis with an
estimated 5-year survival exceeding 90% (Bekkenk et al.,
2000; Liu et al., 2003; Yu et al., 2008). In contrast, primary
cutaneous peripheral T-cell lymphoma not otherwise speci-
fied (PTL-NOS) presents with more generalized skin tumors
and displays aggressive clinical behavior (Willemze et al.,
2005). PTL-NOS, formerly termed CD30-negative large T-cell
lymphoma, frequently disseminates to extracutaneous sites and
is often refractory to chemotherapeutic treatment. Patients with
PTL-NOS have an estimated 5-year survival ofo15% (Beljaards
et al., 1994; Grange et al., 1999; Bekkenk et al., 2003).
The genetic events involved in the pathogenesis of these
cutaneous lymphomas are largely unknown. Cytogenetic
analyses of C-ALCL have shown recurrent copy number
alterations (CNAs) of several chromosomal regions, including
gains on 6p, 7q, and 19, and losses on 6q, 9, and 18 (Boni
et al., 2000; Mao et al., 2003; Prochazkova et al., 2003;
Fischer et al., 2004; Zettl et al., 2004). The t(2;5)(p23;q35)
translocation inducing the nucleophosmin/anaplastic lym-
phoma kinase chimeric protein, a characteristic feature of
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nodal ALCL, is not or only rarely found in C-ALCL (DeCoteau
et al., 1996). To date, no studies on chromosomal alterations
in primary cutaneous PTL-NOS have been published.
Genetic factors responsible for the differences in clinical
behavior of C-ALCL and PTL-NOS, both derived from skin-
homing T cells, have not yet been resolved. Our group has
previously shown that the FAS receptor is expressed by
C-ALCL tumor cells, whereas expression is lost in the majority
of PTL-NOS cases, suggesting differences in sensitivity to
extrinsic pro-apoptotic signals (Zoi-Toli et al., 2000). In
addition, studies have indicated that signaling through the
CD30 receptor is implicated in proliferation and apoptosis of
lymphoid cells in C-ALCL (Mori et al., 1999; Horie et al., 2002).
In this study, array-based comparative genomic hybridiza-
tion (CGH) analysis and gene expression profiling was carried
out on C-ALCL and primary cutaneous PTL-NOS tumor
samples to identify chromosomal aberrations and gene
expression patterns, which may contribute to a better
understanding of the molecular mechanisms involved in the
development and in the differential clinical behavior of these
two types of CTCL.
RESULTS
Recurrent chromosomal alterations in C-ALCL and PTL-NOS
with potential biological significance
Tumor biopsy samples of 11 patients diagnosed with C-ALCL
and 10 patients with PTL-NOS were analyzed for numerical
chromosomal alterations using array-based CGH. Clinical
characteristics of the patients are shown in Table 1 and
immunophenotypical characteristics of the tumor cells are
provided in Table S1. In DNA isolated from all C-ALCL and
PTL-NOS tumor samples, numerous chromosomal alterations
were present. An overview of the cumulative array-based
CGH results in a Frequency of Amplicon, Gain and Loss
(FrAGL) plot is shown in for C-ALCL in Figure 1a and for PTL-
NOS in Figure 1c.
Table 1. Clinical characteristics
No. Sex Age (years) Extent Therapy Result Site of relapse
Current
status
Follow-up
(months)
C-ALCL
1 M 48 LOC RT CR S; LN; LUNG DOD 231
2 F 62 GEN Chemo PR S; LN DOD 36
3 F 74 SOL RT CR S ACR 258
4 F 45 GEN Chemo PR S; LN DOD 308
5 M 69 LOC RT CR — ACR 120
6 M 51 GEN — — S ACR 105
7 M 63 GEN RT PR S AWD 139
8 M 86 LOC RT CR — ACR 29
9 M 70 SOL RT CR S ACR 12
10 F 79 SOL RT CR ACR 13
11 F 44 LOC EXC CR S AWD 62
PTL-NOS
12 M 33 GEN Chemo PR S; LN; CNS DOD 13
13 M 65 SOL Chemo PR S; CNS DOD 8
14 F 80 GEN Chemo PR S; LN DOD 27
15 M 70 GEN Chemo PR S DOD 13
16 M 75 GEN Chemo PD BLOOD DOD 1
17 M 73 GEN Chemo PR S; LN DOD 14
18 M 58 GEN Chemo PD DOD 31
19 F 65 GEN Chemo PD S; LN; BM DOD 12
20 M 33 GEN Chemo PD S; CNS DOD 19
21 M 59 GEN Chemo PR DOD 61
ACR, alive in complete remission; AWD, alive with clinical symptoms of disease; BM, bone marrow; chemo, chemotherapy; C-ALCL, cutaneous anaplastic
large cell lymphoma; CNS, central nervous system; CR, complete remission; DOD, death by disease; EXC, excision; F, female; GEN, generalized (multifocal)
skin disease; LN, lymph node; LOC, localized disease; M, male; PD, progressive disease; PR, partial remission; PTL-NOS, peripheral T-cell lymphoma not
otherwise specified; RT, radiotherapy; S, skin; SOL, solitary lesion.
1Died of therapy-related side effects.
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The overall pattern of chromosomal alterations of C-ALCL
is characterized by gains of large regions on chromosome 7q
and 17 and losses of regions on chromosome 6q and 13. To
delineate chromosomal regions harboring genes with patho-
biological relevance, we determined the minimal common
regions (MCRs), the smallest recurrent chromosomal region
with altered probes common to the set of array-based CGH
profiles (Rouveirol et al., 2006). A total of 30 MCRs present in
at least 35% of the patients were identified. MCRs are
visualized in the averaged chromosomal pattern of C-ALCL as
vertical bands in Figure 1b and are listed in Table 2. Of these
recurrent MCRs with CNA, 20 represent gains of chromoso-
mal regions and 10 correspond to losses. The most highly
recurrent chromosomal alterations are gain of 7q31 and loss
of 13q34 and 6q16-6q21, all affecting 45% of patients. Next,
we cross-referenced the genes residing in these 30 MCRs with
the Cancer Gene Census, a list of genes for which mutations
have been causally implicated in cancer (Futreal et al., 2004).
As presented in Table 2a, the MCRs harbored 26 known
oncogenes and tumor suppressor genes. The most highly
recurrent MCR with gain in C-ALCL at 7q31 harbors a single
oncogene, the MET gene that encodes the hepatocyte growth
factor receptor. Three putative tumor suppressor genes,
CDC16, CUL4A, and PRDM1 reside in the loci with loss on
13q34 and 6q16-6q21.
The pattern of CNAs of PTL-NOS is predominated by gains
of large regions on chromosome 7, 8, and 17 (Figure 1c).
Thirty-four MCRs affecting at least 35% of patients were
identified, including 30 gains and only 4 losses (Figure 1d,
Table 2). The most highly recurrent MCRs with CNA are 7q36
affected by gain in 60% of patients and 7q21-7q22, 8p12-
8q12, 8p21.1-8q21.3, and 8q22-8q24.2, each showing gain
in 50% of patients. Forty-three known cancer-associated
genes, listed in Table 2b, are located in MCRs with recurrent
CNA. Although no confirmed oncogenes are located on
7q36, it harbors the FASTK gene encoding an anti-apoptotic
kinase expressed by T cells (Simarro et al., 2007). The MYC
oncogene, previously shown to be amplified and over-
expressed in Se´zary syndrome and also in aggressive B-cell
lymphomas, is located in the MCR with gain on 8q22-8q24.2
(Mossafa et al., 2006; Vermeer et al., 2008).
Similarities and differences between chromosomal alterations
in C-ALCL and PTL-NOS
The cumulative patterns of chromosomal alterations of
C-ALCL and PTL-NOS show many overlapping features. C-
ALCL and PTL-NOS are concordant with respect to gain of
large chromosomal regions on 7q and 17. These chromo-
somes contain several MCRS with CNA that affect both
of these lymphomas, such as gains on 7q21-7q22 and
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Figure 1. Visualization of the array-based CGH data using VAMP. Chromosomes are indicated on the horizontal axis; excluded are the X and Y chromosomes.
Gains are depicted in red and losses in green. (a) Frequency of Amplicon, Gain and Loss (FrAGL) plot for C-ALCL tumor samples. (b) Averaged CGH pattern of
C-ALCL tumor samples. MCRs with loss occurring in at least 35% of patients are indicated as green vertical lines and MCRs with gain as red vertical lines.
(c) FrAGL plot for PTL-NOS tumor samples. (d) MCRs with loss occurring in at least 35% of patients indicated as green vertical lines and MCRs with gain
indicated as red vertical lines in the averaged CGH pattern of PTL-NOS tumor samples.
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17q21-17q25. Other MCRs in C-ALCL and PTL-NOS that have
in common are gain of 6p21.3 and losses on 8p21-22 (Table 2).
However, clear differences exist between the CNA
patterns of C-ALCL and PTL-NOS. Most strikingly, gains on
chromosome 8 affect the majority of patients with PTL-NOS,
but are almost absent in C-ALCL. On the other hand, C-ALCL
tumor samples were distinguished by frequent losses on
chromosome 6 and 13. A distinction of potential relevance
concerns the 9p21 locus, which is not affected by loss in any
of the C-ALCL patients, but is deleted in 50% of PTL-NOS
patients (Figure 1c). The deleted region is quite large in most
patients and contains a MCR located on 9p21.3 harboring the
CDKN2A tumor suppressor gene.
Gene expression patterns of C-ALCL and PTL-NOS show
marked differences
To gain insight into the gene expression programs of the
tumor cells that underlie the difference in clinical behavior of
these entities, gene expression profiling was performed.
Supervised gene expression analysis showed that 547 probe
sets targeting 358 genes were significantly differentially
expressed. Of these genes, 325 were relatively higher
Table 2a. Minimal common regions C-ALCL
Chromosome
Cytogenetic
band CNA Clone start Clone end
Position
start
Position
end
No. of Cases
affected Genes
6 6q16-6q21 Loss RP3-454N4 RP3-454N4 104,974,085 107,020,676 5 PRDM1*
7 7q31 Gain RP11-328M22 RP11-126C19 110,975,058 118,629,320 5 MET
13 13q34 Loss RP11-310D8 RP11-265C7 110,681,700 114,142,980 5 CDC16*, CUL4A*
1 1p36.2 Gain RP11-285P3 RP11-285P3 12,462,984 15,425,500 4
6 6q25-6q27 Loss RP3-336G18 RP1-137D17 156,122,661 170,373,241 4 MLLT4, FGFR1OP
7 7q21 Gain RP11-28I21b RP5-1093O17 80,528,144 84,729,683 4
7 7q21 Gain RP11-212B1 RP5-1084H12 85,485,924 91,973,205 4 AKAP9
7 7q21 Gain RP11-101N13 RP5-1145A22 92,090,477 97,314,287 4
7 7q21-7q22 Gain RP4-550A13 RP11-44M6 97,314,794 100,976,355 4
7 7q32-7q34 Gain RP11-193I17 RP11-269N18 130,792,900 139,186,224 4 TIF1
7 7q34 Gain RP11-237G17 RP5-894A10 140,558,165 142,236,215 4
7 7q35 Gain RP5-819O4 RP4-811H12 144,233,517 147,084,269 4
7 7q35-7q36 Gain RP5-1136G13 RP4-800G7 147,259,180 149,650,854 4
8 8p22-8p21 Loss RP11-369E15 RP11-529P14 18,644,291 22,394,183 4
13 13q12-13q14 Loss RP11-550P23 RP11-351K3 29,008,462 45,700,578 4 FOXO1A, BRCA2,
LHFP, LCP1
17 17q12-17q21 Gain RP11-94L15 RP11-58O9 34,979,298 36,236,729 4 ERBB2, RARA
21 21q22 Gain RP5-1031P17 RP1-171F15 39,702,870 41,559,383 4
1 1p36.3 Loss RP4-785P20 RP11-49J3 1,145,847 7,059,893 3
1 1q21-1q23 Gain RP1-13P20 RP11-15G16 148,424,834 161,212,962 3 NTRK1, PRCC, TPM3,
SDHC, ARNT, FCGR2B, MUC1
3 3p26-3p25 Loss RP11-167K17 RP11-329A2 6,636,703 8,869,825 3
6 6p21.3 Gain RP5-1077I5 RP1-93N13 32,200,774 33,467,588 3
7 7p22-7p21 Gain RP4-733B9 RP5-1100A7 6,234,587 12,919,070 3 PMS2
8 8p23-8p22 Loss RP11-104F14 RP11-19N21 1,706,678 17,782,553 3
16 16p11.2-16q11.2 Loss RP11-274A17 RP11-274A17 32,345,186 45,067,244 3
17 17p13 Loss RP11-186B7 RP11-199F11 7,063,252 7,563,870 3 TP53
17 17p11.2 Gain RP5-836L9 RP11-121A13 19,748,613 21,055,083 3 USP6
17 17q21-17q22 Gain RP11-361K8 RP11-312B18 43,043,105 49,753,469 3 COL1A1
17 17q23 Gain RP11-178C3 RP11-156L14 54,872,929 59,626,448 3 CLTC, NACA, BRIP1
17 17q25 Gain RP11-87G24 GS-362-K4 72,271,167 78,774,742 3 MSF
17 17p11.2 Gain RP1-162E17 RP1-162E17 18,114,679 19,211,694 3
C-ALCL, cutaneous anaplastic large cell lymphoma; CNA, copy number alteration; MCR, minimal common region.
Start and end positions are delineated by the nearby borders of adjacent clones. Genes are the cancer census genes situated in the subsequent MCRs.
In addition, genes indicated with an asterisk are referred to in the Results and Discussion sections.
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expressed in C-ALCL and 33 showed higher expression in
PTL-NOS. A heatmap, indicating gene expression intensities
across the samples, showing the 91 most differentially
expressed genes with a ratio of geometric means (RGM)
exceeding 2.5 is depicted in Figure 2a and b. To illustrate the
expression of these 91 genes in benign CD4þ T cells, we
Table 2b. Minimal common regions PTL-NOS
Chromosome
Cytogenetic
band CNA Clone start Clone end
Position
start
Position
end
No. of
Cases
affected Genes
7 7q36 Gain RP4-548K24 RP4-548D19 149,838,701 151,558,264 6 FASTK*
7 7q21-7q22 Gain RP4-550A13 RP5-1059M17 97,314,794 101,175,494 5
8 8p12-8q12 Gain RP11-44K6 RP11-114M5 38,488,992 61,676,214 5 FLAG1
8 8q21.1-8q21.3 Gain RP11-34M16 RP11-120I21 82,095,683 87,610,633 5
8 8q22-8q24.2 Gain RP11-21E8 RP11-3O20b 101,431,725 130,562,466 5 MYC, EXT1
7 7q11.2 Gain RP11-313P13 RP11-107L23 71,274,704 76,190,020 4 HIP1
7 7q32 Gain RP11-128A6 RP5-999D10 127,266,861 129,658,047 4 SMO
8 8p23 Gain GS-580-L5 RP11-104F14 0 2,817,096 4
8 8p23-8p22 Gain RP11-589N15 RP11-809L8 10,796,421 18,447,618 4 PCM1
9 9p13-9p12 Loss RP11-211N8 RP11-211N8 40,774,565 46,771,375 4
12 12q13 Gain RP5-1057I20 RP11-302B13 46,299,979 48,258,682 4
17 17p11.2 Gain RP11-189D22 CTB-1187M2 17,521,462 19,614,077 4 USP6
17 17q21 Gain RP5-1110E20 RP5-1169K15 35,920,940 41,095,565 4 BRCA1, ETV4,
17 17q21 Gain RP11-220N20 RP11-506D12 41,565,972 46,429,569 4 COL1A1
17 17q25 Gain RP11-478P5 RP11-313F15 69,639,765 77,988,928 4 MSF
1 1q32 Gain RP11-383G10 RP11-534L20 202,933,682 205,087,972 3 SLC45A3
6 6p21.3 Gain RP1-93N13 RP11-175A4 32,498,505 33,876,274 3
8 8p23 Loss RP3-461F17 RP11-177H2 2,304,174 11,802,558 3
8 8p22-8p21 Loss RP11-161I2 RP11-529P14 18,450,010 22,394,183 3
9 9p21 Loss RP11-149I2 RP11-149I2 21,158,465 22,479,496 3 CDKN2A-p14ARF,
CDKN2A-p16(INK4a)
11 11p15 Gain CTC-1277H1 CTC-1277H1 16,774,089 18,095,206 3
11 11q13 Gain RP11-126P21 RP5-901A4 66,035,373 68,072,319 3
11 11q13 Gain RP11-554A11 RP11-31L22 68,278,585 72,378,220 3 CCND1, NUMA1
11 11q23-11q25 Gain RP11-35P15 RP11-215D10 116,368,601 120,790,891 3 MLL, CBL, ARHGEF12,
PCSK7, BMPR1A, DDX6,
PAFAH1B2
11 11q24-11q25 Gain RP11-432I22 GS-770-G7 124,761,526 134,156,487 3 FLI1
12 12p13 Gain GS-124-K20 RP11-264F23 0 5,163,995 3 CCND2
12 12q13 Gain RP11-474N8 RP11-181L23 55,007,887 56,286,203 3 DDIT3
14 14q31-14q32 Gain RP11-257P13 RP11-257P13 88,987,033 91,389,787 3
16 16q12.1 Gain RP11-305A7 RP11-147B17 47,397,787 49,618,230 3 CYLD
17 17q22_27 Gain RP11-372K20 RP11-112J9 49,922,957 52,616,475 3 HLF
17 17q22-17q23 Gain RP11-567L7 RP11-332H18 54,280,512 57,301,021 3 CLTC, NACA, BRIP1
17 17q23-17q24 Gain RP11-156L14 RP11-89H15 58,038,015 61,192,768 3
19 19p13.3-19p13.1 Gain RP5-859H16 RP11-943H6 5,138,666 19,023,191 3 ELL, TPM4, BRD4,
LYL1, MLLT1
19 19q12-19q13.4 Gain CTC-325L16 GS-325-I23 36,979,850 63,806,651 3 ERCC2, BCL3, AKT2,
CEBPA, CIC, TFPT, ZNF331
CNA, copy number alteration; MCR, minimal common region; PTL-NOS, peripheral T-cell lymphoma not otherwise specified.
Start and end positions are delineated by the nearby borders of adjacent clones. Genes are the cancer census genes situated in the subsequent MCRs.
In addition, genes indicated with an asterisk are referred to in the Results and Discussion sections.
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made use of published transcriptome data acquired using the
same microarray platform (Piccaluga et al., 2007). A heatmap
illustrating transcript abundance can be found in Figure S1.
Expression of the majority of genes differentially expressed
between C-ALCL and PTL-NOS is low in benign CD4þ T
cells. A complete list of the differentially expressed genes can
be found in Table S3. Genes with the relatively highest
expression in C-ALCL are CCR10 and TNFRSF8/CD30. PTL-
NOS showed higher expression of several genes including
Protein Kinase C theta (PRKCQ), Fyn binding protein, and
several GIMAP genes.
As CNAs contribute to oncogenesis by altering the
expression of resident genes, we assessed the possible
relationship between altered expression and the presence of
gains and losses of specific chromosomal regions in these
lymphomas. For the most significantly differentially expressed,
the frequency of gain or loss of the corresponding chromo-
somal region in the two lymphomas was evaluated. As
apparent in Figure 2, many genes relatively overexpressed in
C-ALCL were located in a chromosomal region that was
frequently affected by gain in C-ALCL (TNFRSF8/CD30,
CCR7, and CCR10), or less often in a region with loss in
PTL-NOS (TMOD1). Conversely, theGIMAP 1, 4, and 6 genes,
relatively overexpressed in PTL-NOS, reside in chromosomal
regions commonly showing gain in this malignancy. The
number of samples per diagnostic group was insufficient to
carry out a comprehensive integrative analysis by correlating
expression of each individual gene to the presence of CNA of
the corresponding chromosomal region.
Pathway analysis shows that C-ALCL and PTL-NOS differ in
particular with respect to expression of genes involved in
chemotaxis, apoptosis, and lymphocyte proliferation
Next, to interpret the comparative gene expression data and
to extract information regarding biological processes and
signaling pathways that may distinguish these lymphomas,
we carried out knowledge-based pathway analysis. Gene
Ontology (GO) analysis of the most differentially expressed
genes showed significant enrichment of six GO clusters;
these are depicted in Figure 2c with their respective P-values.
Genes belonging to these enriched clusters are marked in
Figure 2a and b. The lymphoma types, C-ALCL and PTL-NOS
in particular, differed in expression of gene clusters with a
role in chemokine receptor activity (CCR10, CCR7,
CNTNAP1, CCR8), apoptosis (TNFRSF8/CD30, JMY, RFFL,
TMEM23/SGMS1, TRAF1, HIP1, PMAIP1, CDKN2C/p18) and
lymphocyte proliferation (PRKCQ). This result is consistent
with the observed difference in extracutaneous dissemination
and treatment resistance of these CTCLs.
Quantitative real-time PCR and immunohistochemistry confirm
gene expression results
To validate the results of gene expression analysis, transcript
abundance of selected genes was measured using quantita-
tive real-time PCR (qPCR) in the C-ALCL and PTL-NOS tumor
samples, as well as in CD4þ T cells from healthy individuals
used as benign reference (Figure 3). Genes with a role in
chemotaxis (CCR10, CCR7), apoptosis (TNFRSF8/CD30,
TRAF1), T-cell activation, and proliferation (IRF4/MUM1,
PRKCQ) were analyzed. In addition, expression levels of the
cytokine receptor gene IL23R and of the oncogenic Polycomb
gene EZH2 were quantified. qPCR analysis confirmed
significant differential expression found in microarray-based
gene expression analysis of all tested genes. Expression levels
differed between C-ALCL and PTL-NOS with fold changes
ranging from 3.8 (TRAF1) to 131.5 (CCR7). The genes
encoding the chemokine receptors CCR10 and CCR7
appeared to be selectively expressed in tumors of C-ALCL
patients. Moreover, the expression of IRF4/MUM1, a tran-
scription factor that regulates T-cell apoptosis, was markedly
higher in C-ALCL than in PTL-NOS or CD4þ T cells.
Expression of TRAF1, encoding a protein that relays signals
from TNFRSF8/CD30, was significantly higher in C-ALCL
than in PTL-NOS. Conversely, transcript levels of PRKCQ
were higher in PTL-NOS than in C-ALCL and CD4þ T cells
(fold change of 10.9 and 4.6, respectively). The PRKCQ gene
is exclusively expressed by T cells and functions as a
downstream target of the T-cell receptor, relaying signals
required for activation and survival after stimulation by
antigen (Bertolotto et al., 2000; Villalba et al., 2001; Hayashi
and Altman, 2007). Abundant expression of PRKCQ has been
noted previously in T-cell leukemias and lymphomas
(Villalba and Altman, 2002). For these reasons, we con-
sidered it a prime candidate oncogene in PTL-NOS. As
oncogenes, in particular kinases, can be activated through
activating mutations in addition to overexpression, we
carried out analysis of the coding region of PRKCQ for
mutations potentially resulting in constitutive activity of its
kinase domain. This failed to show any mutations in the
included PTL-NOS tumor samples (data not shown).
In addition, the expression of IRF4/MUM1 and TRAF1
genes was investigated on the protein level using immuno-
histochemistry. Stainings were carried out on samples
included in this study for genomic profiling as well as on
additional C-ALCL cases not included in this study. Staining
of more than 50% of the neoplastic T cells for IRF4/MUM1
and TRAF1 genes was observed in 31 of 31 (100%) and 26 of
31 (84%) cases of C-ALCL, but not in any of the 15 PTL-NOS
cases. Results of exemplary stainings are shown in Figure 4.
Figure 2. Comparative analysis of gene expression profiles of 11 C-ALCL and 10 PTL-NOS tumor samples. Heatmap depicting gene expression intensities of
significantly differentially expressed genes (SAM algorithm, false discovery rate 0.1). Values are visualized according to the scale bar that represents the
difference in expression relative to the mean expression. Red represents high, black represents intermediate, and blue represent low expression. (a) Genes
showing higher expression in C-ALCL compared with PTL-NOS with a ratio of geometric means (RGM) higher than 2.5. (b) Genes expressed at lower levels in
C-ALCL than in PTL-NOS with a RGMo0.4. The last two columns show the percentage of C-ALCL and PTL-NOS cases affected by chromosomal alterations at
the locus where each differentially expressed gene resides. (c) Results of Gene Ontology analysis, showing gene clusters involved in the biological processes for
which significant enrichment was discovered. Genes belonging to these clusters are indicated in a separate column ‘‘cluster’’ in panels a and b; the numbers
refer to the clusters designated in panel c.
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In a report on TRAF1 expression, Assaf et al. (2007) described
strong TRAF1 expression in only 1 of 28 (4%) C-ALCL cases.
Kempf et al. (2008) have described IRF4/MUM1 expression in
only 2 of 10 cases of C-ALCL. Consistent with our results,
more recent immunohistochemical studies have shown IRF4/
MUM1 and TRAF1 expression in 80–100% of C-ALCL cases
(Wasco et al., 2008; Benner et al., 2009; Feldman et al.,
2009).
DISCUSSION
C-ALCL and primary cutaneous PTL-NOS are two distinct
types of CTCL that are both derived from skin-homing T cells,
but show marked differences in clinical behavior and
prognosis. Array-based CGH analysis allowed identification
of recurrent chromosomal alterations harboring candidate
oncogenes and tumor suppressor genes in these lymphoma
types. Although both C-ALCL and PTL-NOS showed gains of
large regions on chromosome 7 and 17, C-ALCL was
distinguished by additional losses on chromosome 6 and 13
and PTL-NOS by gains on chromosome 8 and losses on
chromosome 9. Detailed analysis of CNAs in C-ALCL showed
that the most highly recurrent MCR with gain was located on
7q31 and loss on 6q16-6q21 and 13q34, each affecting 45%
of the patients. The focal MCR with gain on 7q31 harbors the
MET oncogene. MET amplification has previously been
shown to result in its increased expression in nodal ALCL
(Gogusev et al., 2002) and deregulated expression has been
noted in adult T-cell leukemia (Pons et al., 1998; Choi et al.,
2007). The MCR with loss on 6q16-6q21 contains the
PRDM1/BLIMP-1 gene encoding a transcription factor that
is implicated in T-cell homeostasis and differentiation. In
mice lacking PRDM1/Blimp-1 activity, accumulation of
CD4þ T cells is observed (Kallies et al., 2006; Martins
et al., 2006). Other cancer-associated genes located in
regions with recurrent CNA with potential relevance in the
pathogenesis of C-ALCL include FOXO1A and BRCA2 on
13q12-13q14 (loss in 36%), PRDM16/MEL1 on 1p36 (gain in
27%), and TP53 on 17p13 (loss in 27% of patients). We have
identified previously unreported recurrent chromosomal
alterations in C-ALCL and confirmed several gains and losses
found in the few studies in which conventional CGH was
applied. Consistent with our results, Zettl et al. (2004)
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Figure 3. Expression levels of selected genes as measured by qPCR. Cumulative mRNA expression data of C-ALCL (n¼ 11) and PTL-NOS (n¼10)
(mean±SEM). The mRNA expression was measured relative to RPS11 and U1A used as reference genes. Fold change for transcript levels of genes with increased
expression in C-ALCL compared with PTL-NOS: TNFRSF8, 12.9; IL23R, 9.7; EZH2, 6.5; IRF4, 13.0; CCR10, 25.0; CCR7, 131.5; and TRAF1, 3.8. The fold
change for the level of PRKCQ expression, overexpressed in PTL-NOS compared with C-ALCL, was 10.9.
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observed gain of regions on 7q and 6p in 2 of 11 C-ALCL
samples. Mao et al. (2003) described gains of 1p, 5, 6, 7, 8p,
and 19, showing partial overlap with our findings. In a group
of seven patients with relapsing C-ALCL, Prochazkova et al.
(2003) observed recurrent gain of regions on chromosome 9
and losses on chromosome 6 and 18. Furthermore in nodal
ALCL, recurrent CNAs affecting 7q and 13q have been
described (Zettl et al., 2004; Salaverria et al., 2008).
In PTL-NOS, the most frequently affected MCR with gain
was 7q36. This focal region contains the anti-apoptotic
FASTK gene that is overexpressed in association with
chromosomal gain in mycosis fungoides (Simarro et al.,
2007; van Doorn et al., 2009). Similar to primary cutaneous
PTL-NOS studied herein, tumor cells of PTL-NOS presenting
in lymph nodes have been reported to be affected by
recurrent gains on chromosome 7q22-qter (Zettl et al.,
2004), 17q11-q25, and 8q (Thorns et al., 2007). A major
difference between the chromosomal alterations observed in
PTL-NOS and C-ALCL concerns the occurrence of gains on
chromosome 8. These were highly recurrent in PTL-NOS, but
did not or scarcely affect patients with C-ALCL. A MCR with
gain on 8q22-8q24.2 affecting 50% of PTL-NOS patients
contains the MYC oncogene that is amplified in patients with
Se´zary syndrome and aggressive B-cell lymphomas (Mossafa
et al., 2006; Vermeer et al., 2008). Gain of chromosome 8q
was previously recognized in aggressive CTCLs with shorter
survival (Karenko et al., 2003; Fischer et al., 2004).
Furthermore, we found that the 9p21 locus was affected by
loss in 50% of the patients with PTL-NOS, whereas it
was not deleted in any of the included C-ALCL patients. The
9p21 region contains the CDKN2A tumor suppressor gene,
loss of which is associated with an unfavorable prognosis in
patients with nodal and cutaneous lymphomas (Pinyol et al.,
1998). Our results contrast with those of Boni et al. (2000),
who detected loss of 9p21 in a subset of patients with
C-ALCL.
Second, gene expression analysis showed marked differ-
ences in expression patterns of gene sets in C-ALCL and PTL-
NOS. In an effort to unravel these patterns of differentially
expressed genes and search for biological functions and
signaling pathways distinct in these lymphomas, we applied
unbiased GO analysis. This showed significant enrichment
for gene clusters implicated in chemokine receptor activity,
apoptosis, lymphocyte proliferation, and several other
biological processes. These observed differences may be
associated with the differential clinical behavior of C-ALCL
and PTL-NOS.
Chemokine receptors determine homing patterns of T cells
and serve to mark specific T-cell subsets. C-ALCL tumor
biopsies showed higher expression of the chemokine receptor
genes CCR10, CCR8, and CCR7 relative to PTL-NOS.
Interestingly, the genes encoding CCR10 and CCR7 are
located in chromosomal regions that are frequently affected
by copy number gain in C-ALCL. CCR10 marks a subset of
memory T cells with skin-homing capacity (Soler et al.,
2003). Binding of its ligand CCL27, which is selectively
produced in the skin, recruits T cells to the cutaneous
microenvironment (Homey et al., 2002). CCR10 expression
has been described previously in mycosis fungoides and
Se´zary syndrome, but not specifically in C-ALCL or PTL-NOS
(Notohamiprodjo et al., 2005; Fujita et al., 2006; Capriotti
et al., 2007). Moreover, CCR8 is preferentially expressed
by T cells resident in the skin (Schaerli et al., 2004). The
higher tendency of PTL-NOS lymphoid cells to display
extracutaneous dissemination may result from lower affinity
of these cells for the cutaneous microenvironment because
of low expression of the skin-homing receptors CCR10
and CCR8.
Unbiased comparative analysis of the gene expression
programs of C-ALCL and PTL-NOS tumors showed differ-
ential expression of a gene cluster involved in apoptosis.
Defective apoptosis signaling is presumed to have
Figure 4. Immunohistochemical staining of TNFRSF8/CD30, IRF4/MUM1,
and TRAF1 in C-ALCL and PTL-NOS. HE stainings showing the morphology of
C-ALCL (A1) and PTL-NOS (B1) tumor cells. The tumor cells of C-ALCL
strongly express TNFRSF8/CD30 (A2), TRAF1 (A3), and IRF4/MUM1 (A4).
PTL-NOS tumor cells do not or only scarcely show positive staining for
TNFRSF8/CD30 (B2), TRAF1 (B3), and IRF4/MUM1 (B4). Bar¼ 100mm.
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an important role in the pathogenesis of C-ALCL and
PTL-NOS, as the homeostasis of mature T cells from which
these lymphomas are derived is predominantly governed by
selective induction of cell death (Kikuchi and Nishikawa,
1997). Both C-ALCL and PTL-NOS lymphoid cells are
assumed to show apoptosis impairment compared with
benign CD4þ T cells from which these lymphomas are
derived. The occurrence of spontaneous tumor regression in a
subset of patients with C-ALCL and the higher sensitivity of
C-ALCL to therapy suggest that apoptosis impairment in this
lymphoma type is less pronounced than in PTL-NOS.
Accordingly, C-ALCL and PTL-NOS showed altered expres-
sion of different sets of apoptosis-regulatory genes. C-ALCL
showed relative high expression of IRF4/MUM1, TNFRSF8/
CD30, and TRAF1 and diminished expression of CDKN2C/
p18. qPCR analysis and immunohistochemistry confirmed
increased expression of IRF4/MUM1 and TRAF1 by C-ALCL
lymphoid cells, also relative to normal CD4þ T cells. IRF4/
MUM1 protects CD4þ T cells against pro-apoptotic stimuli
and activation-induced cell death (Lohoff et al., 2004).
Moreover, TRAF1, involved in the intracellular signal
transduction of CD30 and other tumor necrosis factor
receptors, is believed to protect T cells from apoptosis
induced by various stimuli (Durkop et al., 2003). Therefore,
aberrant expression of IRF4/MUM1 and TRAF1 may result in
increased resistance to apoptosis in C-ALCL lymphoid cells.
On the contrary, PTL-NOS was characterized by high
expression of PRKCQ and diminished expression of FAS
and Caspase 10. The PRKCQ gene relays signals required for
T-cell activation and survival after stimulation by antigen
(Bertolotto et al., 2000; Villalba et al., 2001; Hayashi and
Altman, 2007) It has been suggested that PRKCQ may have
oncogenic activity in T-cell malignancies and may serve as a
therapeutic target using Protein kinase C inhibitors (Zhou
et al., 1999; Villalba et al., 2001; Villalba and Altman, 2002).
The PRKCQ gene was overexpressed relative to C-ALCL as
well as to normal CD4þ T cells. Additional mutational
analysis failed to detect activating mutations in these
PTL-NOS tumor samples. Loss of expression of the FAS
receptor is another mechanism through which PTL-NOS
tumor cells can acquire resistance to pro-apoptotic stimuli.
The FAS mRNA expression data from this study are consistent
with previous studies showing that protein expression of the
FAS receptor is lost in the majority of PTL-NOS tumor cells,
whereas it is expressed in C-ALCL (Zoi-Toli et al., 2000).
Taken together, C-ALCL and PTL-NOS have distinct
patterns of chromosomal abnormalities, which may in part
explain their different clinical behavior. We were able to
identify several candidate oncogenes and tumor suppressor
genes residing in MCRs with highly recurrent gains and
losses in these T-cell lymphomas. The more aggressive
clinical behavior of PTL-NOS may, in part, be related to
chromosomal gains of regions on chromosome 8 and losses
affecting 9p21, as decreased p16 and p14ARF expression
resulting from such loss has been found to predict poor
prognosis in various lymphomas (Dijkman et al., 2006).
Importantly, the distinct clinical behavior of these CTCLs is
paralleled by differences in their gene expression programs
linked to T-cell homing, apoptosis, and proliferation.
Lymphoid cells of patients with C-ALCL show higher
expression of skin-homing receptors, which may explain
their higher affinity for the skin and lower tendency to
disseminate into extracutaneous sites than PTL-NOS tumor
cells. Furthermore, C-ALCL and PTL-NOS are characterized
by dysregulated expression of different sets of apoptosis-
regulating genes, which may account for differences in
treatment resistance and tendency to progress.
MATERIALS AND METHODS
Selection of patients
Pretreatment biopsies of 11 patients with C-ALCL and 10 patients
with primary cutaneous PTL-NOS were selected for this study
(Table 1). In all 21 cases, the biopsies contained more than
75% malignant T cells. The immunophenotypical characteristics of
the 21 cases are presented in Table S1. All patients had been
retrieved from the database of the Dutch Cutaneous Lymphoma
Group, reviewed by an expert panel of dermatologists and
hematopathologists before entry in this database and classified using
criteria of the WHO-EORTC classification for the primary cutaneous
lymphomas (Willemze et al., 2005). In all patients, routine staging
procedures including physical examination, complete and
differential blood cell counts and serum biochemical analysis,
computed tomography scan of the neck, chest, and abdomen and a
bone marrow biopsy had been negative. With respect to the group of
primary cutaneous PTL-NOS, these cases did not meet the criteria of
one of the rare subtypes of primary cutaneous PTL-NOS (aggressive
epidermotropic CD8þ CTCL; cutaneous gamma-delta T-cell
lymphoma; CD4þ small/medium pleomorphic CTCL), and none of
them had a history of or concurrent patches and plaques suggesting a
diagnosis of mycosis fungoides. Of 10 patients with PTL-NOS,
9 presented with generalized ulcerating tumors. CD30 staining
was either completely negative (eight cases) or showed expression
by a minor proportion (o25%) of neoplastic T cells (cases 20 and
21). Approval for these studies was obtained from the institutional
review board of the Leiden University Medical Center. Informed
consent was provided according to the Declaration of Helsinki
Principles.
Extraction of RNA and DNA
In all cases, DNA and RNA were isolated from the same frozen
tumor biopsy sample for array-based CGH and microarray-based
gene expression analysis, qPCR, and mutation analysis. RNA was
extracted from 25 50mM frozen sections using the RNeasy Kit
(Qiagen, Hilden, Germany), yielding 25–60mg total RNA. DNA was
isolated from 25 frozen sections (20 mM) using the Genomic-tip 20/G
kit (Qiagen), yielding 10–60 mg genomic DNA.
Array-based CGH analysis
Genome-wide analysis of CNAs was carried out using array-based
CGH containing B3,500 bacterial artificial chromosomes (BACs)
produced at the Leiden University Medical Center. The particular
BAC set used to produce the arrays was distributed by the Wellcome
Trust Sanger Institute (Hinxton, UK) and contains large insert clones
spaced atB1Mb density over the full genome, a set of subtelomeric
sequences for each chromosome arm, and a few hundred probes
selected for their involvement in oncogenesis (Knight et al., 2000).
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Fabrication and validation of the array, hybridization methods, and
analytical procedures have been described elsewhere in detail
(Knijnenburg et al., 2005). Data were analyzed using CAPweb
(Institut Curie, Paris, France) and visualized using VAMP (Institut
Curie, Paris, France) (La Rosa et al., 2006). Copy number was
classified as normal, copy number gain (log2 ratio 40.25), or
genomic loss (log2 ratio o 0.25). Identified CNA of regions with
copy number variations described in the Database of Genomic
Variants (http://projects.tcag.ca/variation) were excluded from analysis.
Gene expression profiling
Samples and microarrays (Human Genome U133plus2.0 array,
Affymetrix, Santa Clara, CA), interrogating over 47,000
human transcripts and variants, were processed according to the
manufacturer’s protocol as described previously (Dijkman et al.,
2007). The microarray images were quantified using the Genechip
operating system (GCOS; v1.2 software) (Affymetrix). The 260 of 280
ratios of isolated RNA were 41.8 for all samples, as
measured using a NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE), confirming RNA purity. RNA integrity
was determined by gel electrophoresis, which showed two
ribosomal RNA bands with the 28S rRNA band having a higher
intensity than the 18S rRNA band in all cases. In addition, we used
the internal controls present on the Affymetrix arrays allowing
monitoring of RNA quality after hybridization. The 30/50 GAPDH and
30/50 b-actin values were within the limits recommended by
Affymetrix (maximally 1.25 and 3, respectively) for all samples.
The average fluorescence intensity was determined for each
microarray and then the output of each experiment was globally
scaled to a target value of 200. The profiles of normal CD4þ T cells
were obtained from the GEO database (accession numbers
GSM146182–GSM146186) previously published by Piccaluga
et al. (2007). They obtained the CD4þ T cells by positive selection
using magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Normalization and variance stabilization was carried out
using VSN in the R statistical software package (Huber et al., 2002).
Data analysis
BAC clone and oligonucleotide probe positions were established
based on Ensembl (Ensembl is a joint project between European
Bioinformatics Institute (EBI), an outstation of the European
Molecular Biology Laboratory (EMBL), and the Wellcome Trust
Sanger Institute (WTSI), Hinxton, United Kingdom) release 44 (April
2007). Recurrent MCRs with CNA affecting at least 35% of analyzed
samples were computed in CAPweb using the algorithm proposed by
Rouveirol et al. (2006). MCRs consisting of only subtelomeric clones
were not taken into consideration. The nearby borders of adjacent
clones were chosen to delineate MCRs. Candidate genes with
pathobiological relevance were selected by focusing on genes listed
as oncogene or tumor suppressor gene in the Cancer Gene Census
list (November 2008) (Futreal et al., 2004). Comparative analysis of
the gene expression patterns of C-ALCL and PTL-NOS was carried
out using BRB-ArrayTools v3.5.0 (http://linus.nci.nih.gov/BRB-Ar-
rayTools.html) using the significance analysis of microarray algo-
rithm, with a false discovery rate of 0.1, performing 100
permutations. The DAVID (National Cancer Institute, Frederick,
MD) bioinformatics database was used for GO enrichment analysis
(Dennis et al., 2003). Genes most significantly differentially
expressed with a RGM higher than 2.5 or lower than 0.4 were
analyzed with highest stringency for enriched GO clusters. By means
of the gene location, the associated BAC clone was determined, for
genes not located in the region of a BAC clone the most proximate
clone spotted on the array was taken. For these BAC clones, the
percentage of CNAs was calculated.
qPCR
cDNA synthesis was performed on 1mg total RNA, after treatment
with RQ1 DNase I (Promega, Madison, WI), using IScript reverse
transcriptase (Bio-Rad, Veenendaal, the Netherlands), oligo(dT)1218,
and random hexamer priming (Bio-Rad) in a final volume of 20 ml.
qPCR was performed using the MyIQ Detection System and the
SYBR Green Supermix (Bio-Rad). The cycle parameters for tran-
scripts of interest and for the reference genes U1A and RPS11 used
for normalization were as follows: denaturing for 15 seconds at
97 1C; annealing and extension for 20 seconds at 60 1C, for 40
cycles. Primer sequences (Invitrogen, Breda, the Netherlands) are
given in Table S2. Data were evaluated using MyIQ software (Bio-
Rad) and the second derivative maximum algorithm, whereas
confirmation of the specificity of the PCR product and standard
curves were performed as previously described (Dijkman et al.,
2007). Freshly isolated CD4þ T cells of four healthy donors were
used as controls for qPCR experiments.
Mutation analysis
Mutation analysis of the coding region of the PRKCQ gene was
carried out on cDNA from eight biopsy samples of patients with PTL-
NOS. Primer sequences are listed in Table S2. The PCR fragments
were purified and directly subjected to sequence reactions. The
software Mutation Explorer (SoftGenetics, LLC, State College, PA)
was applied for analyzing sequences and comparing with reference
sequences from the NCBI database (National Center for Biotechno-
logy Information, Bethesda, MD).
Immunohistochemistry
Immunohistochemical analysis of the protein expression of
TNFRSF8/CD30, TRAF1, and IRF4/MUM1 was carried out on the
21 C-ALCL and PTL-NOS samples selected for genomic analyses. In
addition, paraffin-embedded sections of an independent set consist-
ing of 20 C-ALCL and 5 PTL-NOS samples were subjected to
immunohistochemical staining. Immunostaining was performed with
antibodies against TNFRSF8/CD30 (DAKO, Glostrup, Denmark),
TRAF1, and IRF4/MUM1 using a standard three-step streptavidin–-
biotin–peroxidase-based technique after antigen retrieval with
microwave heating, as described previously (Hoefnagel et al.,
2006). The antibodies against IRF4/MUM1 and TRAF1 were kindly
provided by Professor Dr G Cattoretti (Institute of Cancer Genetics,
Columbia University, New York, USA) and Professor Dr. H. Du¨rkop
(Institute of Pathology, Charite´, Berlin, Germany), respectively.
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